Triple

T21327539
Position Surface form Disambiguated ID Type / Status
Subject Larry Bock E525800 entity
Predicate coFounded P104 FINISHED
Object Neurocrine Biosciences NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Neurocrine Biosciences | Statement: [Larry Bock, coFounded, Neurocrine Biosciences]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Neurocrine Biosciences
Context triple: [Larry Bock, coFounded, Neurocrine Biosciences]
  • A. Alkermes
    Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
  • B. Mapp Biopharmaceutical
    Mapp Biopharmaceutical is a U.S.-based biotechnology company best known for developing antibody-based therapies for infectious diseases, including experimental treatments for Ebola.
  • C. BioMarin Pharmaceutical
    BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
  • D. Vertex Pharmaceuticals
    Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
  • E. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Neurocrine Biosciences
Target entity description: Neurocrine Biosciences is a biopharmaceutical company specializing in the discovery and development of treatments for neurological and endocrine-related disorders.
  • A. Alkermes
    Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
  • B. Mapp Biopharmaceutical
    Mapp Biopharmaceutical is a U.S.-based biotechnology company best known for developing antibody-based therapies for infectious diseases, including experimental treatments for Ebola.
  • C. BioMarin Pharmaceutical
    BioMarin Pharmaceutical is a biotechnology company specializing in developing and commercializing therapies for rare genetic diseases.
  • D. Vertex Pharmaceuticals
    Vertex Pharmaceuticals is a biotechnology company best known for developing transformative therapies for cystic fibrosis and other serious diseases using a precision medicine approach.
  • E. Biogen
    Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b51b90788190a4dd823d962626da completed April 16, 2026, 10:08 a.m.
NER Named-entity recognition batch_69e7ab4d69b4819088649e34213d0b67 completed April 21, 2026, 4:52 p.m.
Created at: April 16, 2026, 4:41 p.m.